| ²é¿´: 1088 | »Ø¸´: 2 | |||
LCqingboгæ (СÓÐÃûÆø)
|
[½»Á÷]
IND£¨ÐÂÒ©ÁÙ´²Ñо¿)£¬ÓÐÒ»¶ÎÓ¢ÎÄ˵Ã÷£¬²»Àí½âɶÒâ˼ ÒÑÓÐ1È˲ÎÓë
|
|
Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
» ²ÂÄãϲ»¶
ËÓÐÈËÎÀ°æ ¡¶¶¾Àíѧ»ù´¡¡·µÚÆß°æÊé¼®
ÒѾÓÐ0È˻ظ´
[ÇóÖú] Á÷ʽËÀ»îȾ & µ¥Ï¸°ûÃÅ¿ØÉèÖñ»ÖÊÒÉ£¬ÈçºÎÓÅ»¯²¢½âÊÍ£¿
ÒѾÓÐ1È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ236È˻ظ´
µ°°×Îȶ¨ÐÔʵÑéÓ빦ÄÜʵÑé²»Ò»ÖÂ
ÒѾÓÐ11È˻ظ´
µÚ4ÄêÁË£¬ÂíÉÏ40ÁË£¬¿ÉÄÜÎÒÓë¹ú»ùȷʵÎÞÔµ°É¡£¡£¡£
ÒѾÓÐ12È˻ظ´
26ÓÐûÓÐÀÏʦÏëÊÕ×ö¶¨Á¿Ò©ÀíµÄѧÉú°¡
ÒѾÓÐ3È˻ظ´
2026ÄêÉ격ҩѧרҵ
ÒѾÓÐ1È˻ظ´
26¿¼²©ÉêÇë ѧorר
ÒѾÓÐ15È˻ظ´
ҩѧר˶É격
ÒѾÓÐ3È˻ظ´
lyblyb1212
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 21
- ºì»¨: 2
- Ìû×Ó: 10
- ÔÚÏß: 6.7Сʱ
- ³æºÅ: 1836701
- ×¢²á: 2012-05-27
- ÐÔ±ð: GG
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
|
ÔÎÄ£ºCurrent Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. ·Ò룺ÏÖÐеÄÁª°î·¨Âɹ涨£¬ÔÚÒ©Æ·ÔËÊä»ò·Ö·¢µ½¸÷ÖÝǰ£¬Ò©Æ·Ó¦µ±¾Åú×¼ÔÊÐíÉÏÊС£ ÓÉÓÚÉê°ìÕß¿ÉÄÜÏ뽫Ñо¿ÓÃÒ©ÎïÔËË͵½¸÷ÖݵÄÁÙ´²Ñо¿Õߣ¬Òò´Ë±ØÐëѰÇó»íÃâ¸Ã·¨ÂÉÒªÇó¡£ IND¾ÍÊÇÉê°ìÕß´Ó¼¼ÊõÉÏ»ñµÃFDA»íÃâµÄÊֶΡ£ |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
2Â¥2017-12-28 16:44:32
LCqingbo
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 812.8
- Ìû×Ó: 66
- ÔÚÏß: 5.8Сʱ
- ³æºÅ: 7498381
- ×¢²á: 2017-11-20
- רҵ: ºÏ³ÉÒ©Îﻯѧ
3Â¥2017-12-28 17:45:12














»Ø¸´´ËÂ¥
LCqingbo